Organovo to Test Pre-Clinical Drugs on Bio-Printed Kidney Tissue
Xconomy
SEPTEMBER 9, 2016
It’s been almost two years since Organovo (NYSE: ONVO ) created a new business—using its bio-printing technology to create 3-D samples of living human liver tissue for use in testing the toxicity of pre-clinical drug candidates. We look at ourselves as a human tissues company…We’ll test your compound in our lab as a service.”.
40 
Let's personalize your content